Zonampanel

Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.^[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials.^[5]

Zonampanel

Clinical data
ATC code	None
Identifiers
IUPAC name [7-(1H-Imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydro-1(2H)-quinoxalinyl]acetic acid
CAS Number	210245-80-0
PubChem CID	148200
ChemSpider	130649
UNII	9X33544ILS
CompTox Dashboard (EPA)	DTXSID50175232
Chemical and physical data
Formula	C13H9N5O6
Molar mass	331.244 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cn(cn1)c2cc3c(cc2[N+](=O)[O-])[nH]c(=O)c(=O)n3CC(=O)O
InChI InChI=1S/C13H9N5O6/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22/h1-4,6H,5H2,(H,15,21)(H,19,20) Key:SPXYHZRWPRQLNS-UHFFFAOYSA-N